Front line therapy with gemcitabine(G) administered immediately prior to pemetrexed (P) for patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Final report of a phase II clinical

被引：0
|
作者：
West, H. J.
Belt, R. J.
Wakelee, H. A.
Monberg, M. J.
Frye, L. A.
Ye, Z.
Obasaju, C. K.
机构：
[1] Swedish Canc Inst, Seattle, WA USA
[2] Kansas City Canc Ctr, Kansas City, MO USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：393S / 393S
页数：1
相关论文
共 50 条
  • [1] Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial.
    West, H
    Belt, RJ
    Wakelee, HA
    Bloss, LP
    Taylor, L
    Monberg, MJ
    Ye, Z
    Obasaju, CK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 649S - 649S
  • [2] Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial.
    McCleod, M
    Treat, J
    Christiansen, NP
    Mintzer, DM
    Bonomi, P
    Bloss, LP
    Taylor, L
    Monberg, MJ
    Ye, Z
    Obasaju, CK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 650S - 650S
  • [3] A PHASE II TRIAL OF PEMETREXED (P), GEMCITABINE (G), AND BEVACIZUMAB (BV) IN UNTREATED PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Wozniak, Antoinette
    Kalemkerian, Gregory
    Gadgeel, Shirish M.
    Ramnath, Nithya
    Schneider, Bryan
    Valdivieso, Manuel
    Smith, Daryn
    Hackstock, Deborah
    Chen, Wei
    Ruckdeschel, John
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1234 - S1235
  • [4] A phase II trial of pemetrexed (P), gemcitabine (G), and bevacizumab (BV) in untreated patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Wozniak, A. J.
    Kalemkerian, G. P.
    Gadgeel, S. M.
    Schneider, B. J.
    Valdivieso, M.
    Venkatramanamoorthy, R.
    Hackstock, D. M.
    Chen, W.
    Heilbrun, L. K.
    Ruckdeschel, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] A phase II trial of pemetrexed (P), gemcitabine (G), and bevacizumab (BV) in untreated patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Wozniak, Antoinette J.
    Kalemkerian, Gregory P.
    Gadgeel, Shirish M.
    Schneider, Bryan J.
    Valdivieso, Manuel
    Smith, Daryn
    Hackstock, Deborah M.
    Chen Wei
    Heilbrun, Lance K.
    Ruckdeschel, John D.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S454 - S454
  • [6] Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: A phase II trial
    Treat, Joseph
    Bonomi, Philip
    McCleod, Michael
    Christiansen, Neal P.
    Mintzer, David M.
    Monberg, Matthew J.
    Ye, Zhishen
    Chen, Ruqin
    Obasaju, Coleman K.
    LUNG CANCER, 2006, 53 (01) : 77 - 83
  • [7] A phase II study of docetaxel (D) and gemcitabine (G) as second-line treatment in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Agelaki, S
    Papadakis, E
    Tsiafaki, X
    Rapti, A
    Toubis, M
    Bania, E
    Kalbakis, K
    Kouroussis, C
    Androulakis, N
    Georgoulias, V
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S256 - S256
  • [8] Pemetrexed plus gemcitabine as front-line therapy for patients with advanced stage non-small cell lung cancer.
    Treat, J
    McCleod, M
    Mintzer, D
    Christiansen, N
    Bonomi, P
    Monberg, M
    Taylor, L
    Obasaju, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 648S - 648S
  • [9] Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial
    West, H. L.
    Wakelee, H. A.
    Perry, M. C.
    Belt, R. J.
    Chen, R.
    Obasaju, C.
    ANNALS OF ONCOLOGY, 2009, 20 (05) : 850 - 856
  • [10] Phase II clinical trial of kahalalide F (KF) as a second line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Provencio, Mariano
    Izquierdo, Angel
    Vinolas, Nuria
    Paz-Ares, Luis
    Feliu, Jaime
    Constenla, Manuel
    de las Heras, Begona
    Erustes, Mercedes
    Izquierdo, Miguel A.
    Rosell, Rafael
    ANNALS OF ONCOLOGY, 2006, 17 : 225 - 225
12345